PI Insights S01E02 | Where Are the Boundaries of Bladder Preservation? — The Clinical Rationale and Technical Foundation Behind the Expanded Enrollment Criteria of HOPE-02/03

PI Insights S01E02 | Where Are the Boundaries of Bladder Preservation? — The Clinical Rationale and Technical Foundation Behind the Expanded Enrollment Criteria of HOPE-02/03

In the previous episode, we reviewed the full evolution of the HOPE series from HOPE-01 through HOPE-04. Among all its design features, one detail may represent the most distinctive — and perhaps boldest — aspect of the HOPE program within the global bladder-preservation landscape: its enrollment criteria.
PI Perspectives S01E03 | Finding Balance in the Chemo-Immunotherapy Era — A Strategic Dialogue Between HOPE-02, NIAGARA, RETAIN-02, and INDI-BLADE

PI Perspectives S01E03 | Finding Balance in the Chemo-Immunotherapy Era — A Strategic Dialogue Between HOPE-02, NIAGARA, RETAIN-02, and INDI-BLADE

In the previous episode, we explored the clinical rationale and technical safeguards behind the expanded enrollment criteria of HOPE-02/03. In this installment, we place HOPE-02 within the broader landscape of perioperative and bladder-preservation research in muscle-invasive bladder cancer (MIBC) to better understand its position among contemporary global studies.
Cancer Communications | Professor Shi Yanxia and Professor An Xin’s Team Explores a New Post-Resistance Treatment Strategy for Advanced Urothelial Carcinoma

Cancer Communications | Professor Shi Yanxia and Professor An Xin’s Team Explores a New Post-Resistance Treatment Strategy for Advanced Urothelial Carcinoma

On April 21, 2026, Professor Shi Yanxia and Professor An Xin’s team from Sun Yat-sen University Cancer Center published their latest findings in the international journal Cancer Communications under the title “Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study.”
CUDA Yanqi Lake Conference | Professor Xiaodong Wen : From Evidence to Practice — How Real-World Precision Therapy Addresses Clinical Challenges in Urologic Oncology

CUDA Yanqi Lake Conference | Professor Xiaodong Wen : From Evidence to Practice — How Real-World Precision Therapy Addresses Clinical Challenges in Urologic Oncology

Randomized controlled trials (RCTs), regarded as the “gold standard” of evidence-based medicine, serve as the cornerstone for establishing oncology treatment guidelines. However, it is equally important to recognize that the strict inclusion and exclusion criteria of RCTs often create a significant gap between trial populations and the realities of everyday clinical practice, where many patients are elderly, have multiple comorbidities, or have experienced failure of several prior treatment lines.
“Deep Dive Debate” | After Achieving pCR with Immunotherapy in TNBC, Should Adjuvant Immunotherapy Be Continued or Stopped?

“Deep Dive Debate” | After Achieving pCR with Immunotherapy in TNBC, Should Adjuvant Immunotherapy Be Continued or Stopped?

With the success of landmark clinical studies such as KEYNOTE-522, neoadjuvant treatment for early-stage triple-negative breast cancer (TNBC) has fully entered the era of immunotherapy combined with chemotherapy. While this strategy has significantly improved pathological complete response (pCR) rates and delivered substantial survival benefits, it has also raised one of the most debated questions in current clinical practice:
2026 CSCO BC Guideline Highlights | Professor Jiayi Chen: Key Updates in Breast Cancer Radiotherapy

2026 CSCO BC Guideline Highlights | Professor Jiayi Chen: Key Updates in Breast Cancer Radiotherapy

The 2026 National Breast Cancer Conference was held in Beijing from April 10–12, during which major updates to the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2026 (CSCO BC Guidelines 2026) were officially released. At the meeting, Professor Jiayi Chen from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, reviewed and interpreted the latest updates in the radiotherapy section of the guidelines.
2026 CSCO BC Guideline Highlights | Professor Chunfang Hao: Key Updates in Salvage Endocrine Therapy for HR-Positive Advanced Breast Cancer — Multi-Directional Strategies, Precision Assessment, Optimized Combinations, and Sequential Multi-Target Therapy

2026 CSCO BC Guideline Highlights | Professor Chunfang Hao: Key Updates in Salvage Endocrine Therapy for HR-Positive Advanced Breast Cancer — Multi-Directional Strategies, Precision Assessment, Optimized Combinations, and Sequential Multi-Target Therapy

The 2026 National Breast Cancer Conference was held in Beijing from April 10–12, during which the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2026 (CSCO BC Guidelines 2026) underwent major updates. At the meeting, Professor Chunfang Hao from Tianjin Medical University Cancer Institute and Hospital delivered a comprehensive overview of the latest advances in the management of HR-positive breast cancer.
2026 CSCO BC Guideline Highlights | Professor Kun Wang: Key Updates in Neoadjuvant and Adjuvant Management of HER2-Positive Early Breast Cancer

2026 CSCO BC Guideline Highlights | Professor Kun Wang: Key Updates in Neoadjuvant and Adjuvant Management of HER2-Positive Early Breast Cancer

The 2026 National Breast Cancer Conference was held in Beijing from April 10–12, during which important updates to the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2026 (CSCO BC Guidelines 2026) were officially released. At the meeting, Professor Kun Wang from Guangdong Provincial People’s Hospital presented and interpreted the latest updates in neoadjuvant and adjuvant treatment strategies for early breast cancer.
2026 CSCO Guidelines Conference | Academician Jinming Yu: Strengthening China-Based Evidence, Advancing Global Guideline Outreach, and Bringing Standardized Cancer Care to the Grassroots Level

2026 CSCO Guidelines Conference | Academician Jinming Yu: Strengthening China-Based Evidence, Advancing Global Guideline Outreach, and Bringing Standardized Cancer Care to the Grassroots Level

The 2026 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference was grandly held in Harbin from April 24–25. Bringing together more than a thousand experts, the meeting focused on guideline updates, intelligent healthcare, and multidisciplinary collaboration, with a strong emphasis on extending standardized cancer care to grassroots medical institutions and narrowing regional disparities in oncology practice.